本次董事会经过了适当的通知程序，会议的召集、召开和表决程序符合《中 华人民共和国公司法》等相关法律法规和公司章程的规定，会议及通过的决议合 法有效。 | 证券代码：603108 | 证券简称：润达医疗 | 公告编号：临 2025-028 | | --- | --- | --- | | 转债代码：113588 | 转债简称：润达转债 | | 上海润达医疗科技股份有限公司 董事会决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、董事会会议召开情况 上海润达医疗科技股份有限公司（以下简称"公司"）第五届董事会第二十 三次会议通知于 2025 年 6 月 10 日以邮件形式发出，会议于 2025 年 6 月 13 日（星 期五）10:00-11:00 在上海市虹口区乍浦路 89 号星荟中心 1 座 8 楼公司会议室以 现场及通讯相结合的方式召开。会议应到董事 11 人，实到董事 11 人（其中董事 姚沈杰、周晓兰、何嘉、冯国富因工作等原因以通讯方式参会），公司监事严晨、 吴伟钟、丁秋泉和高级管理人员廖上林列席了会议。会议由 ...

Core Viewpoint - The rapid development of the private equity investment sector has led to A-share listed companies engaging in various forms of private equity investments to discover and incubate quality targets within their industry and supply chains, while also expanding their investment paths. CVC funds led by listed companies have become a crucial force in the private equity market, but they face scrutiny due to potential conflicts of interest and regulatory restrictions, particularly after the implementation of the "Private Investment Fund Registration and Filing Measures" on May 1, 2023 [1][14]. Pathways for Establishing Private Fund Managers - A total of 16 private fund managers related to A-share listed companies have been approved by the Asset Management Association of China (AMAC) from May 1, 2023, to May 1, 2025. These include 1 wholly-owned subsidiary, 4 controlled by listed companies, 10 directly or indirectly invested by listed companies, and 1 established by the actual controller of a listed company [2]. Pathway One: Wholly Owned Establishment - Listed companies can establish private fund managers wholly owned by themselves. This pathway is subject to strict regulatory scrutiny due to the potential classification as "quasi-financial" businesses [3][6]. Pathway Two: Controlling Establishment - Listed companies can also establish controlling private fund managers where they hold more than 50% of the shares. However, this pathway has seen limited success due to regulatory concerns, with only 4 such managers registered since the new regulations [3][4]. Pathway Three: Joint Establishment with Third Parties - This pathway involves listed companies partnering with third parties to establish private fund managers, where the listed company acts as a financial or strategic investor. This has proven to be a more viable option, with 10 managers established under this model since the new regulations [4][5]. Pathway Four: Establishment by Actual Controllers - Actual controllers of listed companies can establish private fund managers directly. This pathway is less restricted, provided that the listed company does not directly invest in the fund manager [6][10]. Compliance Points for Each Pathway - Pathways one and two face stricter regulatory requirements due to the direct control by listed companies, necessitating good financial health and adherence to internal decision-making and disclosure procedures [7][8]. - Pathway three requires careful attention to the legitimacy of the investment purpose and compliance with disclosure obligations, especially regarding related party transactions [10][11]. - Pathway four mandates that the actual controller disclose their relationship with the fund manager and comply with related party transaction regulations if the listed company invests in the fund [12][13]. Risk Prevention Measures - Listed companies and their affiliates must be vigilant against risks such as insider trading, conflicts of interest, and the misuse of non-public information. Establishing robust internal controls and compliance mechanisms is essential to mitigate these risks [12][13]. Conclusion - The article summarizes four pathways for listed companies to establish private fund managers, highlighting the regulatory landscape and compliance requirements. The core controversy revolves around the "quasi-financial" risks associated with these activities, emphasizing the need for a balance between industrial investment demands and financial regulatory boundaries. Future policies may exhibit flexibility, recognizing the value of supporting the real economy while preventing unchecked capital expansion [14].

Investment Rating - The industry investment rating is "Positive" (maintained) [3] Core Insights - The AI application vendors in the US stock market achieved a total revenue of $23.599 billion in Q1 2025, with a year-over-year growth of 12.1%, and an average revenue growth rate of 20.37% [1][11] - The IT service vendors in the US stock market reported a total revenue of $37.612 billion in Q1 2025, reflecting a year-over-year increase of 5.59% [1][34] - The willingness of enterprises to invest in AI is rapidly growing, with expectations for global enterprise software and IT service spending to reach $1.25 trillion and $1.73 trillion in 2025, respectively [2][56] Summary by Sections 1. Industry Perspective: AI Deployment Demand Growth Opens SaaS and IT Service Market Space - AI application vendors in the US stock market showed significant improvement in profitability and operational efficiency in Q1 2025, with a combined net profit of $4.774 billion, a year-over-year increase of 55.76% [1][13] - The average operating profit margin for these vendors was 15.81%, up by 1.61 percentage points year-over-year [1][17] - The combined RPO (Remaining Performance Obligation) for AI application vendors reached $132.266 billion in Q1 2025, a year-over-year growth of 16.48% [1][26] 2. Tracking Overseas AI Application Vendors - Salesforce reported a revenue of $9.829 billion in Q1 2026, with a year-over-year growth of 7.62% [2][67] - Adobe's AI-first related product orders exceeded $125 million in Q1 2025, with expectations to double by the end of FY25 [2][33] - HubSpot's Copilot user base grew to over 660,000 in Q1 2025, reflecting a significant increase from 270,000 in Q4 2024 [2][33] 3. Recommendations for Focused Targets - Suggested targets include companies involved in Agent applications such as iFlytek and Focus Technology, as well as AI vertical applications like Kingsoft Office and Foxit Software [3]

Core Points - The article discusses the collaborative development and mutual empowerment between Baiyun District and Mazhang District, highlighting the achievements and ongoing initiatives in cultural heritage, economic development, and community welfare [3][4][25]. Financial Support and Investment - Baiyun District has invested a total of 120 million yuan in financial support over the past two years, implementing 41 assistance projects and raising an additional 8.043 million yuan from various social sources [3]. - The total investment from 28 enterprises attracted to Mazhang District amounts to 9.6 billion yuan [3]. Cultural and Heritage Initiatives - The "Cultural and Natural Heritage Day" event showcased the cultural products developed through Baiyun's support, including the launch of a creative design competition for packaging "intangible cultural heritage" gifts [3][4]. - The promotion of local cultural assets, such as the "Mazhang Six Treasures," has increased the district's visibility and reputation [15][21]. Economic Development and Industrial Growth - The integration and optimization of the Mazhang Economic Development Zone have been approved, focusing on key industries such as forestry, high-end equipment, and supporting sectors like seafood processing and biomedicine [13][14]. - New projects have been initiated, with five new industrial projects already under construction, reflecting a "land immediately operational" approach [14]. Community and Infrastructure Development - Significant investments have been made in educational and healthcare services, including training nearly 2,000 teachers and improving medical resources for children in need [23][24]. - Infrastructure projects, such as the establishment of a public transportation system, have enhanced connectivity for residents, benefiting around 200,000 people [22][24]. Collaborative Framework and Future Outlook - The "reverse flying land" model has been established to facilitate resource exchange and collaboration between Baiyun and Mazhang, enhancing the region's attractiveness to businesses and talent [20][21]. - The ongoing efforts aim to create a sustainable and prosperous future for both districts, focusing on industrial strength, rural beauty, and the wealth of the populace [26].

Group 1 - The company has returned all idle raised funds amounting to 180 million yuan to its special account for raised funds, as approved by the board of directors [1][2] - The funds were temporarily used to supplement the company's liquidity for a period not exceeding 12 months [1] - The company has notified the sponsor institution, Guojin Securities Co., Ltd., regarding the return of the funds [1] Group 2 - The company will begin paying interest on its convertible bonds, "Run Da Convertible Bonds," starting from June 17, 2025, for the period from June 17, 2024, to June 16, 2025 [3][4] - The interest payment amount for each bond with a face value of 100 yuan will be 1.80 yuan (including tax) [11][14] - The bond's interest rate for the fifth year is set at 1.8% [11][14] Group 3 - The bond's record date for interest payment is June 16, 2025, and the ex-dividend date is June 17, 2025 [5][15] - The total issuance scale of the convertible bonds is 550 million yuan, with a total of 5.5 million bonds issued [6] - The initial conversion price of the bonds has been adjusted to 13.00 yuan per share as of July 19, 2024, due to profit distribution [10]

上海润达医疗科技股份有限公司（以下简称"公司"）于2024年6月27日召开 了第五届董事会第十四次会议和第五届监事会第十次会议审议通过了《关于使用 闲置募集资金暂时补充流动资金的议案》，同意公司使用闲置募集资金不超过 18,000万元暂时补充流动资金，使用期限自董事会审议批准之日起不超过12个月。 有关详情见公司于2024年6月28日披露的《使用闲置募集资金暂时补充流动资金 的公告》（公告编号：临2024-029）。 截至本公告披露日，公司已将上述用于临时补充公司流动资金的募集资金 18,000万元全部归还至公司募集资金专用账户，并将上述募集资金的归还情况通 知了保荐机构国金证券股份有限公司及保荐代表人。 特此公告。 2025 年 6 月 9 日 关于归还用于暂时补充流动资金的闲置募集资金的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 上海润达医疗科技股份有限公司 | 证券代码：603108 | 证券简称：润达医疗 | 公告编号：临 2025-026 | | --- | --- | --- | | 转债代码：11358 ...

Core Viewpoint - Shanghai RunDa Medical Technology Co., Ltd. announces the interest payment details for its convertible bonds, "RunDa Convertible Bonds," which will begin on June 17, 2025, covering the interest period from June 17, 2024, to June 16, 2025 [1][2]. Group 1: Bond Issuance Overview - The convertible bonds were issued on June 17, 2020, with a total issuance scale of RMB 550 million, equivalent to 5.5 million bonds [4]. - The bonds have a maturity period of 6 years, from June 17, 2020, to June 16, 2026 [2]. - The initial conversion price was set at RMB 13.36 per share, adjusted to RMB 13.25, RMB 13.10, and RMB 13.00 following annual profit distributions in 2021, 2022, and 2023 respectively [5]. Group 2: Interest Payment Details - The interest rate for the fifth year is set at 1.8%, resulting in an interest payment of RMB 1.80 per bond (including tax) [6]. - The bondholders must be registered with China Securities Depository and Clearing Corporation Limited, Shanghai Branch, by June 16, 2025, to receive the interest payment [6]. - The interest payment will be made through the designated bank account of China Securities Depository and Clearing Corporation Limited, and the payment will be distributed to the respective institutions where investors hold their bonds [6]. Group 3: Tax Implications - Individual investors are subject to a 20% personal income tax on the interest income, resulting in a net payment of RMB 1.44 per bond after tax [6][7]. - Non-resident enterprises are exempt from corporate income tax and value-added tax on the interest income until December 31, 2025, under specific regulations [7][8].

| 证券代码：603108 | 证券简称：润达医疗 | 公告编号：临 2025-027 | | --- | --- | --- | | 转债代码：113588 | 转债简称：润达转债 | | 上海润达医疗科技股份有限公司 关于"润达转债"2025 年付息公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 ● 可转债付息债权登记日：2025 年 6 月 16 日 ● 可转债除息日：2025 年 6 月 17 日 ● 可转债兑息日：2025 年 6 月 17 日 （一）债券名称：上海润达医疗科技股份有限公司可转换公司债券 （二）债券简称：润达转债 （三）债券代码：113588 （四）债券类型：可转换为公司 A 股股票的可转换公司债券 （五）发行规模：人民币 55,000 万元 （六）发行数量：5,500,000 手（550,000 张） （七）票面金额和发行价格：每张面值为人民币 100 元，按面值发行。 （八）债券期限：本次发行的可转换公司债券的期限为自发行之日起 6 年， 即 2020 年 6 月 17 日至 2026 年 ...

Core Viewpoint - Jinan Runda Biotechnology Co., Ltd. was fined 600,000 yuan for commercial bribery related to the sale of automatic coagulation analyzers and associated consumables [1][4]. Company Summary - Jinan Runda was found to have engaged in commercial bribery by selling automatic coagulation analyzers and related consumables at low prices to hospitals, thereby gaining more trading opportunities [1][3]. - The company was established in 2014, with a registered capital of 50.5 million yuan, and is primarily owned by Shanghai Runda Medical Technology Co., Ltd., which holds a 70% stake [5]. - The legal representative of Jinan Runda is Li Jie [5]. Parent Company Summary - Shanghai Runda Medical Technology Co., Ltd. was founded in 1999 and went public in 2015. As of March 10, 2025, the largest shareholder is Hangzhou Gongshu District State-owned Investment Group Co., Ltd., holding 19.22% [6]. - Runda Medical acknowledged the commercial bribery incident and stated that it is cooperating with regulatory authorities for investigation and corrective actions [6]. - The company is involved in the IVD (in vitro diagnostics) distribution and service industry, providing diagnostic products and technical support to medical laboratories [6]. Financial Performance - Runda Medical's performance has declined significantly in recent years. In 2024, the company reported revenue of 8.312 billion yuan, a decrease of 9.13% year-on-year, and net profit dropped from 273 million yuan to 55 million yuan, a decline of 79.77% [6][8]. - In the first quarter of 2025, the company reported revenue of 1.662 billion yuan, down 19.81% year-on-year, and a net loss of 69 million yuan, marking a 406.40% decline [8][9]. - The company's total expenses (sales, management, and financial) reached 1.634 billion yuan in 2024, accounting for 19.66% of revenue, an increase of 0.62 percentage points year-on-year [8].

| 证券代码：603108 | 证券简称：润达医疗 | 公告编号：临 2025-025 | | --- | --- | --- | | 转债代码：113588 | 转债简称：润达转债 | | 上海润达医疗科技股份有限公司 关于上月为子公司担保的进展情况公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 一、担保情况概述 （一）为支持上海润达医疗科技股份有限公司（以下简称"公司"）全 资及控股子公司的发展，解决其流动资金短缺问题，经公司董事会及 2024 年度股东大会审议通过：自 2025 年 5 月 27 日至 2025 年度股东大会召开之 日期间，为公司全资及控股子公司向（类）金融机构申请总额不超过人民币 422,100 万元的授信额度提供连带责任保证担保，控股子公司其他股东提供 对等担保或为公司提供足额反担保，公司实际承担出资比例对应的担保金额。 被担保人名称：六家全资子公司：杭州润达、惠中医疗、润达供应链杭 州、中鼎达科、青岛益信、惠中诊断；七家控股子公司：合肥润达、云 南康泰、合肥三立、润达榕嘉、杭州 ...